Clinical Trial Results

Showing 1-10 of 12

Sorted By:

  • A051701 (Lymphoma)

    A Randomized Phase II/III Study of Venetoclax (ABT199) plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas

  • A081105 ALCHEMIST - SUBSTUDY (Lung)

    Randomized Study of Erlotinib VS Observation In Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)


    Adjuvant Nivolumab in Resected Lung Cancers (ANVIL): A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

  • EA8143 PROSPER RCC (Renal)

    A Phase III Randomized Study Comparing Perioperative NIVOLUMAB vs. OBSERVATION in Patients with Renal Cell Carcinoma Undergoing Nephrectomy

  • S1207 (Breast)

    A Phase III Randomized, Placebo- Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor Positive and HER2/NEU Negative Breast Cancer

  • S1320 (Melanoma)

    A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093 in BRAFV600E/K Mutant Melanoma

  • S1400F LUNGMAP - SUBSTUDY (Lung)

    A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LungMAP Non-Match Substudy)

  • S1418-BR006 (Breast)

    A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor Negative Breast Cancer with = 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+)After Neoadjuvant Chemotherapy

  • S1612 (Leukemia)

    Randomized Phase II/III Trial of Novel Therapeutics VS. Azacytadine in Newly Diagnosed patients with AML or High Risk MDS Age 60 or older

  • S1616 (Melanoma)

    A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an ANTI-PD1 or ANTI-PD-L1 Agent